The World Health Organization (WHO) Solidarity Trial testing repurposed drugs known now as “Solidarity PLUS” comes to India to test drugs on 750 hospitalized adult COVID-19 patients. The clinical trial will include study drugs already in use, such as Imatinib targeting select cancers and Infliximab targeting autoimmune diseases such as Crohn’s disease and rheumatoid arthritis. Initiated in 2020, the Solidarity trial investigates the impact of repurposed drugs to help reduce deaths in hospitalized COVID-19 patients as compared to the existing standard of care. WHO’s Solidarity Plus trial spans 52 nations, including India, the world’s second most populated. The study protocol includes three treatment arms, including Artesunate, Infliximab, Imatinib plus the standard of care. The drugs were considered based on the outcome of an independent panel of experts.
Pharma Company Donations
WHO secured donations from the pharmaceutical manufacturers, including Ipca, Johnson and Johnson, and Novartis—all of them agreed to support ongoing access to the treatments at “reasonable prices” should they be proven effective and safe in the study.
While Ipca produced Artesunate to treat malari...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).